We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nivolumab plus Cabozantinib Prolongs Survival in Advanced Renal-Cell Carcinoma.
- Authors
Stewart, Patricia
- Abstract
The article focuses on superior survival outcomes from combination of nivolumab (Opdivo) plus cabozantinib (Cabometyx) as first-line treatment for patients with advanced renal-cell carcinoma (RCC). Topics discussed include superior efficacy of nivolumab plus cabozantinib over sunitinib; approval of nivolumab plus cabozantinib combination by the U.S. Food and Drug Administration; and objective response rate for nivolumab plus cabozantinib.
- Subjects
MEDICAL personnel; CARCINOMA; ADVERSE health care events; TRIPLE-negative breast cancer; METASTATIC breast cancer; COMMERCIAL products
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 4, p1
- ISSN
2164-4403
- Publication type
Article